Current Role and Future Perspectives of Magnetic Resonance Spectroscopy in Radiation Oncology for Prostate Cancer

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2007 Jul 3

PMID 17603627

Citations 9

Authors

Aleksandra Zapotoczna

Giuseppe Sasso

John Simpson

Mack Roach 3rd

Affiliations

Soon will be listed here.

Abstract

Prostatic neoplasms are not uniformly distributed within the prostate volume. With recent developments in three-dimensional intensity-modulated and image-guided radiation therapy, it is possible to treat different volumes within the prostate to different thresholds of doses. This approach has the potential to adapt the dose to the biologic aggressiveness of various clusters of tumor cells within the gland. The definition of tumor burden volume in prostate cancer can be facilitated by the use of magnetic resonance spectroscopy (MRS). The increasing sensitivity and specificity of MRS to the prostate is causing new interest in its potential role in the definition of target subvolumes at higher risk of failure following radical radiotherapy. Prostate MRS might also play a role as a noninvasive predictive factor for tumor response and treatment outcome. We review the use of MRS in radiation therapy for prostate cancer by evaluating its accuracy in the classification of aggressive cancer regions and target definition; its current role in the radiotherapy planning process, with special interest in technical issues behind the successful inclusion of MRS in clinical use; and available early experiences as a prognostic tool.

Citing Articles

Magnetic Resonance Spectroscopy for Cervical Cancer: Review and Potential Prognostic Applications.

Iqbal Z, Albuquerque K, Chan K Cancers (Basel). 2024; 16(11).

PMID: 38893260 PMC: 11171343. DOI: 10.3390/cancers16112141.

Biological imaging in clinical oncology: radiation therapy based on functional imaging.

Lai Y, Wu C, Chao K Int J Clin Oncol. 2016; 21(4):626-632.

PMID: 27384183 DOI: 10.1007/s10147-016-1000-2.

CADOnc: An Integrated Toolkit For Evaluating Radiation Therapy Related Changes In The Prostate Using Multiparametric MRI.

Viswanath S, Tiwari P, Chappelow J, Toth R, Kurhanewicz J, Madabhushi A Proc IEEE Int Symp Biomed Imaging. 2014; 2011:2095-2098.

PMID: 25360226 PMC: 4211635. DOI: 10.1109/ISBI.2011.5872825.

Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells.

Martin A, Hickey J, Ablack A, Lewis J, Luyt L, Gillies E J Nanopart Res. 2012; 12(5):1599-1608.

PMID: 22328862 PMC: 3276591. DOI: 10.1007/s11051-009-9681-3.

A review of image-guided radiotherapy.

Chen G, Sharp G, Mori S Radiol Phys Technol. 2010; 2(1):1-12.

PMID: 20821123 DOI: 10.1007/s12194-008-0045-y.

References

Seshadri M, Spernyak J, Maiery P, Cheney R, Mazurchuk R, Bellnier D . Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia. 2007; 9(2):128-35. PMC: 1813934. DOI: 10.1593/neo.06748. View

Takamiya R, Weinberg V, Young C, Sandler H, McLaughlin P, Roach 3rd M . A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 56(4):1073-8. DOI: 10.1016/s0360-3016(03)00206-2. View

Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M . Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 1999; 44(4):921-9. DOI: 10.1016/s0360-3016(98)00502-1. View

Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach 3rd M . Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60(4):1047-55. DOI: 10.1016/j.ijrobp.2004.05.015. View

Lian J, Xing L, Hunjan S, Dumoulin C, Levin J, Lo A . Mapping of the prostate in endorectal coil-based MRI/MRSI and CT: a deformable registration and validation study. Med Phys. 2004; 31(11):3087-94. DOI: 10.1118/1.1806292. View

Zakian K, Sircar K, Hricak H, Chen H, Shukla-Dave A, Eberhardt S . Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005; 234(3):804-14. DOI: 10.1148/radiol.2343040363. View

Lichy M, Pintaske J, Kottke R, Machann J, Anastasiadis A, Roell S . 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study. Eur Radiol. 2005; 15(4):653-60. DOI: 10.1007/s00330-004-2547-2. View

Venugopal N, McCurdy B, Hnatov A, Dubey A . A feasibility study to investigate the use of thin-plate splines to account for prostate deformation. Phys Med Biol. 2005; 50(12):2871-85. DOI: 10.1088/0031-9155/50/12/010. View

Huisman H, Futterer J, van Lin E, Welmers A, Scheenen T, van Dalen J . Prostate cancer: precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers. Radiology. 2005; 236(1):311-7. DOI: 10.1148/radiol.2361040560. View

10.

Zhao D, Jiang L, Hahn E, Mason R . Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology. Neoplasia. 2005; 7(7):678-87. PMC: 1501423. DOI: 10.1593/neo.04757. View

11.

Pucar D, Shukla-Dave A, Hricak H, Moskowitz C, Kuroiwa K, Olgac S . Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology. 2005; 236(2):545-53. PMC: 2373272. DOI: 10.1148/radiol.2362040739. View

12.

Zietman A, DeSilvio M, Slater J, Rossi Jr C, Miller D, Adams J . Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294(10):1233-9. DOI: 10.1001/jama.294.10.1233. View

13.

Hom J, Coakley F, Simko J, Qayyum A, Lu Y, Schmitt L . Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions. Radiology. 2005; 238(1):192-9. DOI: 10.1148/radiol.2381041675. View

14.

Alterovitz R, Goldberg K, Pouliot J, Hsu I, Kim Y, Noworolski S . Registration of MR prostate images with biomechanical modeling and nonlinear parameter estimation. Med Phys. 2006; 33(2):446-54. DOI: 10.1118/1.2163391. View

15.

McPhail L, McIntyre D, Ludwig C, Kestell P, Griffiths J, Kelland L . Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia. 2006; 8(3):199-206. PMC: 1578525. DOI: 10.1593/neo.05739. View

16.

Scheidler J, Hricak H, Vigneron D, Yu K, Sokolov D, Huang L . Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology. 1999; 213(2):473-80. DOI: 10.1148/radiology.213.2.r99nv23473. View

17.

Yu K, Scheidler J, Hricak H, Vigneron D, Zaloudek C, Males R . Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999; 213(2):481-8. DOI: 10.1148/radiology.213.2.r99nv26481. View

18.

Kurhanewicz J, Vigneron D, Males R, Swanson M, Yu K, Hricak H . The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am. 2000; 38(1):115-38, viii-ix. DOI: 10.1016/s0033-8389(05)70152-4. View

19.

Zaider M, Minerbo G . Tumour control probability: a formulation applicable to any temporal protocol of dose delivery. Phys Med Biol. 2000; 45(2):279-93. DOI: 10.1088/0031-9155/45/2/303. View

20.

Zaider M, Zelefsky M, Lee E, Zakian K, Amols H, Dyke J . Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys. 2000; 47(4):1085-96. DOI: 10.1016/s0360-3016(00)00557-5. View